31 study showed that giving Imfinzi (durvalumab) as adjuvant therapy ... chemoradiotherapy (CRT), based on the results of the PACIFIC trial, carving out a niche for itself away from the dominance ...
The pCR was 37.3% (95% CI, 33.2-41.6) in the durvalumab arm and 27.5% (95% CI, 23.8-31.6) in the comparator arm.
WILMINGTON, Del.--(BUSINESS WIRE)--Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca’s IMFINZI ® (durvalumab), administered ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback